Prediction market traders on Polymarket are nearly certain New York City’s weekend snowfall crossed the 20-inch mark. The 20+ inch outcome now sits at 56%, with over $439,000 in volume on the entire market. The 18–20 inch bracket has collapsed to 36%, and 16–18 inches is down to just 3%.A 20+ inch reading at Central Park has only been recorded six times since 1869, the last being Blizzard Jonas in January 2016, which still holds the all-time record at 27.5 inches.NYSE Expected To OpenMarkets are expected to ...

Gossamer Bio Inc. (NASDAQ:GOSS) dropped during early trading on Monday after the company shared topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertension.PAH is defined by high blood pressure in the lung arteries due to narrowed, damaged, or destroyed vessels, forcing the heart’s right side to overwork and potentially fail.Disappointing Trial DataAt Week 24, patients receiving seralutinib showed a median change of +28.2 meters in the Six-Minute Walk Distance (6 ...

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.1% on Monday.Following the market opening Monday, the Dow traded up 0.06% to 49,655.48 while the NASDAQ fell 0.09% to 22,864.38. The S&P 500 also rose, gaining, 0.06% to 6,913.49.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsEnergy shares gained by 1.2% on Monday.In trading on Monday, consumer discretionary stocks fell by 1.3%.Top HeadlineDomino's Pizza Inc. (NA ...

GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.NHS-Galleri Trial ResultsThe NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.The trial evaluated annual multi-cancer screening with the Galleri test i ...

A tenant representing roughly 2% of annual revenue — approximately $200 million — has defaulted on payments. Consensus estimates still project 6.5% AFFO per share growth.That $2.47 estimate follows a quarter in which American Tower reported continued operating expansion across both its tower and data center segments.In the third quarter of 2025, attributable AFFO per share reached $2.78, representing approximately 10% year-over-year growth. Consolidated revenue increased approximately 8% year over year to $ ...

Brighthouse Financial, Inc. (NASDAQ:BHF) will release earnings results for its fourth quarter during the week of Feb. 23.Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $5.19 per share, up from $5.07 per share in the year-ago period. The consensus estimate for Brighthouse Financial's quarterly revenue is $2.24 billion, versus $2.27 billion a year earlier, according to data from Benzinga Pro.On Feb. 12, Brighthouse Financial's shareholders approved the $4.1 billion ...

Brighthouse Financial, Inc. (NASDAQ:BHF) will release earnings results for its fourth quarter during the week of Feb. 23.Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $5.19 per share, up from $5.07 per share in the year-ago period. The consensus estimate for Brighthouse Financial's quarterly revenue is $2.24 billion, versus $2.27 billion a year earlier, according to data from Benzinga Pro.On Feb. 12, Brighthouse Financial's shareholders approved the $4.1 billion ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying HSIC stock? Here’s what analysts think: Photo via Shutterstock ...

Axial Spondyloarthritis is a chronic, immune-mediated inflammatory disease mainly affecting the spine and sacroiliac joints, often causing chronic back pain, stiffness, and potential spinal fusion.Chronic Back Pain StudyIn the Phase 2 S-OLARIS trial, 81% of patients treated with sonelokimab achieved a clinically meaningful response at Week 12, demonstrating significant improvement in key disease parameters.The trial also confirmed the drug’s ability to reduce inflammation and osteoblast activity in affected ...

Vanda Pharmaceuticals (NASDAQ:VNDA) shares are trading higher during the premarket session on Monday following the announcement of FDA approval for Bysanti (milsaperidone), a new treatment for bipolar I disorder and schizophrenia.FDA ApprovalThe FDA’s approval of Bysanti marks a significant milestone for Vanda, as it is positioned as a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.Bysanti is a new chemical entity (NCE ...